Uva Ursi for Urinary Tract Infection: What the Trials Show

Most herbs on this site have never been tested properly, so the honest verdict is usually “traditional use, unproven.” Uva ursi is different, and that is the whole point of this page. Bearberry leaf (Arctostaphylos uva-ursi) has actually been through modern randomized controlled trials in exactly the population that reaches for it — women with an ordinary, uncomplicated bladder infection. Those trials came back with an answer, the answer was no, and that answer is almost completely absent from the way the herb is sold.

So we are going to do something unusual for a “Benefits” page: lead with the negative result, state it plainly, and only then explain the context. If you are reading this because you have burning and urgency right now and you are hoping a herbal tea will fix it, please read the red flags section before anything else. The single most useful thing this page can give you is not a dose — it is the knowledge that waiting on a urinary infection is not a neutral choice.

The Headline: A Good Trial Said No
Uva Ursi Versus Placebo in Primary Care
Uva Ursi Versus a Single-Dose Antibiotic
How to Read Two Trials That Look Different
The Older Prevention Trial, and Why It Is Not Enough
The Wider Pattern: Non-Antibiotic Strategies Keep Disappointing
Why Delay Is Not Neutral
How Uva Ursi Compares With Cranberry and D-Mannose
Other Claimed Uses and Where They Stand
Evidence Tiers at a Glance
Red Flags: Stop Self-Treating and Get Care
What This Means If You Are Deciding Right Now
Key Research Papers
Connections

The Headline: A Good Trial Said No

Evidence tier: randomized clinical trial.

A well-conducted randomized, placebo-controlled trial of uva ursi extract in women with uncomplicated urinary tract infection found that uva ursi did not shorten how long symptoms lasted compared with placebo, and did not meaningfully reduce how many women went on to need antibiotics. That trial was run in ordinary general practice, in the exact clinical situation the herb is marketed for, with a placebo control and randomization — the design that is hardest to fool.

This is the result that should govern how the herb is discussed, and it is the one you will almost never see on a supplement label. It was published as Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial in Clinical Microbiology and Infection (2019). You can find it and its commentary here: PubMed search: ATAFUTI uva-ursi ibuprofen randomized trial.

Take a moment on why that matters more than it sounds. A negative placebo-controlled trial does not merely mean “we are still unsure.” It means the herb was given a fair chance to beat a sugar pill in real patients and did not do it. Uncomplicated cystitis is a condition where a substantial share of women get better on their own within a week regardless of what they take — which means an ineffective remedy will look like it works to almost everyone who tries it. Personal experience cannot tell these apart. A placebo arm can.

Uva Ursi Versus Placebo in Primary Care

Evidence tier: randomized clinical trial.

The placebo-controlled trial described above used a factorial design: women presenting to their GP with symptoms of a simple lower urinary infection were allocated both to uva ursi extract or a matching placebo, and to advice on taking ibuprofen or not. That layout lets one study answer two questions at once, and it means the uva ursi comparison is genuinely against placebo rather than against “nothing at all,” which is a much weaker test.

What the investigators looked for:

Symptom duration and severity — how many days of frequency, urgency, burning and lower-abdominal discomfort the women actually experienced.
Subsequent antibiotic use — whether taking the herb let women avoid a prescription over the following days.

On the first, uva ursi did not deliver. Symptoms did not resolve faster on the herb than on placebo. On the second, any hint of a difference in antibiotic use was small and not the kind of finding you would build a treatment recommendation on. Where authors describe such a signal, they describe it as a trend requiring confirmation — and no confirming trial has established it since. Treat “it reduces antibiotic use” as not supported by this trial.

There is one honest caveat in the herb's favour, and it belongs here rather than buried at the bottom: a trial can miss a real but small effect. What this trial rules out is a clinically obvious benefit — the kind that would justify choosing a herb over established treatment. It does not prove the extract is biologically inert. But “possibly a small effect we cannot detect” is a very different product from what is sold on the shelf.

Uva Ursi Versus a Single-Dose Antibiotic

Evidence tier: randomized clinical trial — and the more alarming of the two.

The second major trial asked a different and more practical question: if a woman with a simple bladder infection takes uva ursi instead of an antibiotic, what happens? This was the REGATTA trial, published as Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial in Clinical Microbiology and Infection (2021). Its protocol was published earlier in BMC Complementary and Alternative Medicine (2018). Both are findable here: PubMed search: REGATTA uva ursi versus fosfomycin.

The trade-off it found is worth stating carefully, because both halves are true:

Antibiotic use fell. A clear majority of women in the uva ursi arm got through the episode without taking an antibiotic. If the only goal were reducing antibiotic prescriptions, that reads as a win.
They felt worse for longer. Overall symptom burden across the first week was higher in the uva ursi group than in the women who got the single antibiotic dose. The herb did not substitute for treatment; it substituted for relief.
More infections climbed to the kidneys. There were more cases of pyelonephritis — upper urinary tract infection — in the uva ursi arm. The numbers were small in absolute terms, as they always are in a trial of this size, but they pointed the wrong way.

The investigators' own conclusion was that uva ursi cannot be recommended as a first-line alternative to antibiotics for uncomplicated urinary infection. That is not a hedge. That is a trial team who set out hoping to find an antibiotic-sparing option and reported that the one they tested was not it.

How to Read Two Trials That Look Different

People sometimes point at these two trials and say the evidence is “mixed.” It is not really mixed — it is consistent once you notice that they asked different questions.

Against placebo, uva ursi did not shorten symptoms. So there is no demonstrated benefit.
Against an antibiotic, uva ursi left women with more symptoms and more kidney infections. So there is a demonstrated cost to using it as a replacement.

Put those together and the picture is coherent: no proven upside, and a real downside when it displaces treatment. The apparent “win” in the antibiotic trial — fewer prescriptions — is what you would also get by handing out nothing at all, because most simple cystitis resolves eventually. Fewer antibiotics is only a benefit if patients do not pay for it in symptom-days and complications. Here they did.

The Older Prevention Trial, and Why It Is Not Enough

Evidence tier: preliminary (small, old, combination product).

The one positive-looking human study is much older and much weaker. A small preliminary trial published in Current Therapeutic Research in 1993 tested a standardized bearberry preparation — sold as UVA-E, which also contained dandelion — for preventing recurrent cystitis over a year, and reported fewer recurrences than placebo. See PubMed search: UVA-E prophylaxis recurrent cystitis.

Four things keep this from carrying much weight:

It was tiny, and small trials produce large, unreliable effect sizes in both directions.
It was a combination product, so any effect cannot be assigned to bearberry.
It tested prevention, not treatment — a different question from the one most people use the herb for.
It has never been replicated in more than thirty years, despite the herb remaining widely sold. Unreplicated small positives are the single most common way a remedy acquires an undeserved reputation.

There is also a hard problem specific to this herb: prevention means continuous use, and continuous use is exactly what uva ursi's safety ceiling forbids. Even if the 1993 signal were real, the regulatory limit of about a week at a time makes year-round prophylaxis inadmissible. See Preparation, Dosing and Why Duration Is Capped.

The Wider Pattern: Non-Antibiotic Strategies Keep Disappointing

Evidence tier: multiple randomized clinical trials.

Uva ursi is not being singled out. Over the last fifteen years several serious research groups have tested whether uncomplicated cystitis can be managed without antibiotics, using anti-inflammatories rather than herbs, and the results form a pattern.

Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial, BMJ (2015) — the NSAID arm avoided many antibiotic prescriptions but had a longer symptom course and more upper urinary tract infections. PubMed search
Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial, BMJ (2017) — diclofenac was inferior to an antibiotic for symptom resolution, and pyelonephritis occurred only in the NSAID group. PubMed search
Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women — a double-blind, randomized non-inferiority trial, PLoS Medicine (2018) — ibuprofen failed non-inferiority, and again several women in the NSAID arm developed kidney infection while none did on the antibiotic. PubMed search
An earlier pilot comparing ibuprofen with ciprofloxacin, published in BMC Medicine (2010), first raised the same signal. PubMed search

Across these trials the counts of pyelonephritis in the non-antibiotic arms were in the low single digits per study — but consistently higher than in the antibiotic arms, and in some trials the antibiotic arm had none at all. Individually each count is small enough to shrug at. Repeated across independent trials in different countries, it stops being noise.

The relevance to uva ursi is direct. The whole marketing premise of the herb is “you can skip the antibiotic.” The best available evidence on skipping the antibiotic — whether you skip it with a herb or with ibuprofen — is that a minority of women pay for it with a kidney infection. That is not a neutral trade.

Why Delay Is Not Neutral

It helps to understand what is actually happening anatomically. A simple bladder infection is bacteria — usually Escherichia coli — multiplying in the bladder lining. Pyelonephritis is the same bacteria having travelled up the ureters into the kidney. That escalation converts an unpleasant few days into a serious illness: high fever, shaking chills, flank pain, vomiting, and a genuine risk of the infection reaching the bloodstream. It commonly needs intravenous antibiotics and sometimes hospital admission, and in a minority of people it leaves lasting kidney scarring.

So the arithmetic of “wait and see with a herb” is asymmetric. The upside of avoiding an antibiotic course is real but modest — fewer side effects, a little less pressure on resistance. The downside is low-probability but severe. When a trial reports “only a handful more cases of pyelonephritis,” each of those cases is a person who got badly ill in a way that immediate treatment would probably have prevented.

None of this means antibiotics are always the right answer or that antibiotic overuse is not a genuine problem — it is. It means the solution to overuse is better diagnosis and shorter, better-targeted courses, decided with a clinician, not a self-prescribed herb with a negative trial behind it. For background on the condition itself see Urinary Tract Infections and Pyelonephritis.

How Uva Ursi Compares With Cranberry and D-Mannose

Readers usually arrive here having also heard about cranberry or D-mannose, so it is worth placing all three honestly. None of them is a treatment for an infection you already have.

Cranberry — prevention only, modest, better evidence than uva ursi. Systematic reviews in the Cochrane Library have repeatedly examined cranberry products for preventing recurrent urinary infection, and the most recent updates find a reduction in recurrences in some groups, notably women with recurrent UTI and children. The effect is modest and the older reviews were more sceptical, but this is a stronger evidence base than uva ursi has, and cranberry has no hydroquinone problem. Crucially, it is prophylaxis, not therapy. PubMed search: cranberry prevention Cochrane review. See also Cranberries.
D-mannose — preliminary, plausible, under-tested. A randomized study in World Journal of Urology (2014) reported that D-mannose powder reduced recurrences in women with recurrent infection, and the mechanism (blocking bacterial adhesion to the bladder wall) is coherent. But the trial base is thin and larger, better-blinded studies have been less impressive. PubMed search: D-mannose recurrent UTI randomized.
Uva ursi — negative placebo-controlled trial, plus a safety ceiling. Uniquely among the three, it also carries a hard duration limit because its proposed active metabolite is hydroquinone.

An underrated point: the interventions with the best evidence in recurrent UTI are the boring ones — adequate fluid intake, addressing constipation, reviewing contraception and post-menopausal vaginal oestrogen with a clinician, and in selected cases a planned prophylactic strategy. Randomized work on increased daily water intake in women with recurrent cystitis has shown fewer episodes. PubMed search: increased water intake recurrent cystitis trial.

Other Claimed Uses and Where They Stand

Bearberry leaf is also promoted for several things beyond acute cystitis. Here is where each actually sits.

“Urinary antiseptic” and general bladder irritation — traditional use only. The astringent, drying character of the tannin-rich leaf is what earned the reputation, and it is the oldest claim in the file. No modern trial supports it as a treatment.
Diuretic / “water retention” — traditional use only, and a poor reason to take it. Any diuretic effect is unremarkable and shared by drinking more fluid, which carries no hydroquinone.
Antibacterial activity in the laboratory — preliminary (in vitro). Bearberry extracts and hydroquinone inhibit urinary pathogens in a dish, and there is interesting laboratory work on extracts reducing bacterial adhesion and interacting with resistance mechanisms. Petri-dish activity is a starting hypothesis, not evidence of benefit in a person. PubMed search: uva-ursi antibacterial in vitro
Kidney stones / “gravel” — traditional use only, and inadvisable. This is a nineteenth-century indication with no supporting trials, and reduced kidney function is a contraindication. See Kidney Stones.
Skin lightening — different product, do not extrapolate. Arbutin appears in topical cosmetics precisely because it releases hydroquinone, a skin-lightening agent. That is a separate exposure route with its own regulatory history, and it tells you nothing about swallowing the leaf — except that it confirms what the active moiety is.
Interstitial cystitis / bladder pain syndrome — not supported, and potentially harmful. This is a non-infectious condition with an irritated bladder lining; adding an astringent, tannin-heavy, hydroquinone-yielding herb has no rationale. See Interstitial Cystitis.

Evidence Tiers at a Glance

Every claim on this page carries a label. Collected in one place:

Randomized clinical trial — negative. Uva ursi does not shorten symptoms of uncomplicated UTI versus placebo, and does not reliably reduce antibiotic use.
Randomized clinical trial — unfavourable. Used instead of a single-dose antibiotic, uva ursi produced a higher symptom burden and more pyelonephritis.
Randomized clinical trials — consistent warning. Non-antibiotic management of uncomplicated cystitis, herbal or NSAID, repeatedly produces more upper urinary tract infections.
Preliminary. One small, old, unreplicated combination-product trial suggested fewer recurrences with a bearberry/dandelion preparation.
Preliminary (in vitro). Bearberry constituents inhibit urinary bacteria in the laboratory, and bacteria can liberate hydroquinone from arbutin locally.
Traditional use only. Urinary antiseptic, astringent, diuretic, “gravel,” and the requirement for alkaline urine.
Not supported. Uva ursi as a substitute for antibiotic treatment of a diagnosed urinary infection; uva ursi as long-term prophylaxis; uva ursi for interstitial cystitis.

Red Flags: Stop Self-Treating and Get Care

This is the most important list on the page. If any of the following applies, stop considering herbs and arrange medical assessment — today, not next week.

Fever, chills, or feeling systemically unwell. A simple bladder infection does not usually cause fever. Fever suggests the kidney is involved.
Flank or back pain — pain in the side or the small of the back, often on one side, sometimes with tenderness when tapped.
Nausea or vomiting. Both point upward from the bladder, and vomiting also means you cannot reliably keep anything down.
Blood in the urine. Visible blood needs evaluation even when an infection is the likely cause, because it has other causes too.
Pregnancy. Urinary infection in pregnancy is treated promptly because of risks to both mother and baby — and uva ursi is contraindicated in pregnancy regardless.
Male sex. Urinary infection in men is not classed as uncomplicated; it warrants assessment for prostate or structural involvement.
Children. Assessment is needed, and uva ursi is not recommended for children at all.
Recurrent infections — several episodes in a year. This pattern needs a plan and possibly investigation, not repeated self-treatment.
No improvement within 48 hours, or any worsening at any point.
Diabetes, immune suppression, kidney disease, a urinary catheter, a known structural abnormality, or a recent urological procedure. All move the episode out of the “simple” category.
Confusion or new unsteadiness in an older adult, which can be the presenting sign of infection rather than the classic burning.

If you are unsure whether your symptoms even are an infection, a urine dipstick and culture settle it, and culture also tells the clinician which antibiotic will work. See Urinalysis.

What This Means If You Are Deciding Right Now

Stripped to essentials:

Uva ursi is not a treatment for a urinary tract infection. The placebo-controlled trial says it does not shorten symptoms. Nothing published since has overturned that.
Using it in place of treatment has measurable costs — more days of symptoms and more kidney infections in the trial that tested exactly that strategy.
If you have any red flag, seek care. The list above is not defensive boilerplate; it is the part of this page most likely to matter to you.
If you have simple symptoms, no red flags, and want to try conservative measures for a day or two, that is a reasonable conversation to have with a clinician — and the measures with the best evidence are fluids, analgesia and a culture, not bearberry leaf.
If you still choose to use uva ursi, the duration limit is not optional. Read the dosing and duration page and the safety page before you start.
For prevention of recurrence, cranberry has better evidence and no hydroquinone ceiling, and the unglamorous measures beat both.

Uva ursi's real distinction is that it was tested. Most herbs never are, and their reputations survive on that. Bearberry got its trial and the trial did not go its way — which is exactly the sort of finding that ought to change what people do, and usually does not.

Key Research Papers

Citations below are given as PubMed topic searches so they stay valid as records are updated. Titles, journals and years are stated so you can confirm you have the right paper.

Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection, 2019. The placebo-controlled trial at the centre of this page. PubMed search
Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clinical Microbiology and Infection, 2021 (REGATTA). Higher symptom burden and more pyelonephritis in the herbal arm. PubMed search
Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) — a double-blind, randomized, controlled comparative effectiveness trial. BMC Complementary and Alternative Medicine, 2018. The pre-specified design. PubMed search
Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 2015. Fewer antibiotics, longer symptoms, more upper tract infection. PubMed search
Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ, 2017. Diclofenac inferior to antibiotic; pyelonephritis only in the NSAID arm. PubMed search
Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women — a double-blind, randomized non-inferiority trial. PLoS Medicine, 2018. Non-inferiority not met. PubMed search
Prophylactic effect of UVA-E in women with recurrent cystitis: a preliminary report. Current Therapeutic Research, 1993. The small, old, unreplicated positive. PubMed search
Botanical medicines for the urinary tract. World Journal of Urology, 2002. Review placing bearberry among traditional urinary herbs and noting the short-course caveat. PubMed search
Natural approaches to prevention and treatment of infections of the lower urinary tract. Alternative Medicine Review, 2008. Sympathetic review that still describes the bearberry evidence as limited and inconsistent. PubMed search
Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews, updated 2023. The comparator with the better prevention evidence. PubMed search
D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World Journal of Urology, 2014. PubMed search
Uncomplicated urinary tract infection. New England Journal of Medicine, 2012. Standard clinical framing of what “uncomplicated” means and when it stops applying. PubMed search
The diagnosis of urinary tract infection: a systematic review. Deutsches Ärzteblatt International, 2010. Why symptoms alone misclassify a meaningful share of episodes. PubMed search

External Resources

PubMed — the primary literature index used for every citation above.
NCCIH (US National Center for Complementary and Integrative Health) — plain-language herb summaries.
Cochrane Library — systematic reviews, including the cranberry prevention reviews.
European Medicines Agency — publishes the herbal monograph and assessment report that set the duration limit.
NHS — patient-facing guidance on urinary tract infection and when to seek urgent care.

Connections

Safety note. This page is general health education, not medical advice, and it is not a diagnosis. A urinary tract infection can escalate to a kidney or bloodstream infection, and the trial evidence summarised here found more kidney infections when treatment was replaced by uva ursi. Seek prompt medical care for fever, flank or back pain, nausea or vomiting, blood in the urine, symptoms in pregnancy, in a man, or in a child, for recurrent infections, or if you are not clearly improving within 48 hours. Do not use uva ursi in pregnancy or breastfeeding, in children, or if you have kidney or liver disease, and never for longer than the short course described on the dosing page. Talk with a qualified healthcare professional before using any herbal product, especially alongside prescription medicines.

Back to Table of Contents